Ilaria Ottonelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ilaria Ottonelli has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Martin Grabrucker
University of Limerick
1 shared publication - Ann Katrin Sauer
Department of Biological Sciences, University of Limerick, V94 T9PX Limerick, Ireland
1 shared publication - Barbara Ruozi
Nanotech Lab, Te.Far.T.I., Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
1 shared publication - Eleonora Daini
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
1 shared publication - Francesca Pederzoli
Department of Life Sciences Te.Far.T.I. Research Center, University of Modena and Reggio Emilia, 41124 Modena, Italy
1 shared publication - Giovanni Tosi
University of Modena and Reggio Emilia
1 shared publication
Latest Publications
- Open Access
- 1 November 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (11) , 572
Nanomedicine against Aβ Aggregation by β–Sheet Breaker Peptide Delivery: In Vitro Evidence
The accumulation of amyloid β (Aβ) triggers a cascade of toxic events in Alzheimer’s disease (AD). The KLVFF peptide can interfere with Aβ aggregation. However, the peptide suffers from poor bioavailability and the inability to cross the blood–brain barrier. In this work, we study the possibility of adopting nanomedicine to overcome KLVFF limits in biodistribution. We produced new engineered polymeric nanoparticles (NPs), and we evaluated the cellular toxicity of these NPs and validated that KVLFF peptides released by NPs show the same promising effects on AD pathology. Our results revealed the successful generation of KVLFF loaded NPs that, without significant effects on cell heath, are even more potent in reversing Aβ-induced pathologies compared to the free peptide. Therefore, NPs will significantly advance KVLFF treatment as a therapeutic option for AD.
- 1 November 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (11) , 572
Open AccessNanomedicine against Aβ Aggregation by β–Sheet Breaker Peptide Delivery: In Vitro Evidence
The accumulation of amyloid β (Aβ) triggers a cascade of toxic events in Alzheimer’s disease (AD). The KLVFF peptide can interfere with Aβ aggregation. However, the peptide suffers from poor bioavailability and the inability to cross the blood–brain barrier. In this work, we study the possibility of adopting nanomedicine to overcome KLVFF limits in biodistribution. We produced new engineered polymeric nanoparticles (NPs), and we evaluated the cellular toxicity of these NPs and validated that KVLFF peptides released by NPs show the same promising effects on AD pathology. Our results revealed the successful generation of KVLFF loaded NPs that, without significant effects on cell heath, are even more potent in reversing Aβ-induced pathologies compared to the free peptide. Therefore, NPs will significantly advance KVLFF treatment as a therapeutic option for AD.